Search results for "Retrospective studies"

showing 10 items of 3098 documents

Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-E…

2021

Background: Retrospective analyses of clinical trials indicate that elevated serum uric acid (sUA) predicts poor outcome in heart failure (HF). Uric acid can contribute to inflammation and microvascular dysfunction, which may differently affect different left ventricular ejection fraction (LVEF) phenotypes. However, role of sUA across LVEF phenotypes is unknown. Objectives: We investigated sUA association with outcome in a prospective cohort of HF patients stratified according to LVEF. Methods: Through the Heart Failure Long-Term Registry of the European Society of Cardiology (ESC-EORP-HFLT), 4,438 outpatients were identified and classified into: reduced (= 50% HFpEF) LVEF. Endpoints were t…

medicine.medical_specialtyHeart failure030204 cardiovascular system & hematologyVentricular Function Left03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineInternal MedicinemedicineHumansIn patient030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyRetrospective StudiesInflammationEjection fractionbusiness.industryStroke Volumemedicine.diseasePrognosisClinical trialPhenotypechemistryQuartileHeart failureCohortCardiologyUric acidbusinessUric acid
researchProduct

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

2005

Background/Aims: Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy. Methods: Retrospective analysis of data from 1121 adults with chronic hepatitis C treated for 48 weeks with peginterferon alfa-2a (40 KD) 180 mu g/week plus placebo or ribavirin (1000/1200 mg/day), or interferon alfa-2b 3 MIU three times/week plus ribavirin in a randomized, multinational, study. Results: 67% of patients treated with peginterferon alfa-2a (40 KD)/ribavirin with early virological responses (HCV RNA negative or >= 2 log(10) decrease) at week 12 had SVRs at week 72 (HCV RNA 80 % of the planned ribavirin dose. Concl…

medicine.medical_specialtyHepatitis B virusviral hepatitisAlpha interferonPeginterferon-alfaInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundpredictabilityInternal medicineRibavirinmedicinechronic hepatitis CHumansProbabilityRetrospective StudiesHepatitis B viruspeginterferon alfa-2a (40 KD)treatmentHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseasedigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy Combinationsustained virological responseViral hepatitisbusinessViral loadPeginterferon alfa-2amedicine.drugJournal of hepatology
researchProduct

Patient-to-patient transmission of hepatitis C virus (HCV) during colonoscopy diagnosis

2010

Abstract Background No recognized risk factors can be identified in 10-40% of hepatitis C virus (HCV)-infected patients suggesting that the modes of transmission involved could be underestimated or unidentified. Invasive diagnostic procedures, such as endoscopy, have been considered as a potential HCV transmission route; although the actual extent of transmission in endoscopy procedures remains controversial. Most reported HCV outbreaks related to nosocomial acquisition have been attributed to unsafe injection practices and use of multi-dose vials. Only a few cases of likely patient-to-patient HCV transmission via a contaminated colonoscope have been reported to date. Nosocomial HCV infecti…

medicine.medical_specialtyHepatitis C virusMolecular Sequence DataColonoscopyHepacivirusViral Nonstructural Proteinsmedicine.disease_causelcsh:Infectious and parasitic diseaseschemistry.chemical_compoundVirologyEpidemiologyDisease Transmission InfectiousmedicineHumanslcsh:RC109-216NS5BRetrospective StudiesCross InfectionMolecular Epidemiologymedicine.diagnostic_testbusiness.industryTransmission (medicine)ResearchOutbreakRetrospective cohort studyColonoscopySequence Analysis DNAHepatitis Cmedicine.diseaseHepatitis CVirologyInfectious DiseaseschemistryRNA ViralbusinessVirology Journal
researchProduct

Panintestinal capsule endoscopy in patients with celiac disease

2021

INTRODUCTION Capsule endoscopy has proven its utility in diagnosing villous atrophy and lymphoma in patients with celiac disease. Recently, a novel capsule endoscopy system was introduced which enables the examination of the small and large bowel. So far, it has not been evaluated in patients with celiac disease. OBJECTIVE The primary objective of this study was to evaluate the novel panintestinal capsule endoscopy system in patients with celiac disease. METHODS Eleven patients with histologically proven celiac disease (Marsh 0-IV), who underwent a panintestinal capsule endoscopy between March 2018 and April 2019 at our institution, were included in this retrospective single-center study. A…

medicine.medical_specialtyHepatologyDuodenumbusiness.industryConcordanceGastroenterologyDiseasemedicine.diseaseCapsule Endoscopydigestive system diseasesColon polypslaw.inventionCeliac DiseaseCapsule endoscopylawmedicineBowel preparationHumansDuodenal mucosaIn patientRadiologyIntestinal MucosaVillous atrophybusinessRetrospective StudiesEuropean Journal of Gastroenterology & Hepatology
researchProduct

Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A…

2006

Laboratory diagnosis of lysosomal storage disorders, especially sphingomyelinase deficiency (Niemann–Pick disease type A/B) and Niemann–Pick disease type C (NPC) can be challenging. We therefore aimed to analyse the feasibility of first-step screening with specific chitotriosidase cut-off values in children ≤ 10 years of age with visceral organomegaly (hepatomegaly, splenomegaly, or hepatosplenomegaly) in whom a storage disorder was suspected. We conducted a retrospective, cross-sectional, referral, single-centre study to assess diagnostic test properties in 106 individuals. Median chitotriosidase activity was 12 655 nmol/h per ml (interquartile range 4693–20982) in Gaucher disease (GD); 78…

medicine.medical_specialtyHepatosplenomegalyGastroenterologySensitivity and SpecificityOrganomegalyCentral nervous system diseaseDiagnosis DifferentialInterquartile rangePredictive Value of TestsInternal medicineGene DuplicationGenotypeGeneticsMedicineGlycogen storage diseaseHumansChildGenetics (clinical)Retrospective StudiesGaucher Diseasebusiness.industryInfantNiemann-Pick Disease Type CNiemann-Pick Disease Type BNiemann-Pick Disease Type Amedicine.diseaseEndocrinologyHexosaminidasesChemistry ClinicalChild Preschoolmedicine.symptomDifferential diagnosisbusinessNiemann–Pick diseaseJournal of inherited metabolic disease
researchProduct

Systematic search for neutropenia should be part of the first screening in patients with poikiloderma.

2011

Poikiloderma occurs in a number of hereditary syndromes, the best known of which is Rothmund-Thomson syndrome (RTS). Differential diagnoses include Dyskeratosis Congenita (DC) with high genetic heterogeneity and Clericuzio-type Poikiloderma with Neutropenia (CPN) due to mutations in the C16orf57 gene. Mutations in the RECQL4 gene are only observed in two thirds of RTS patients. In this study, 10 patients referred for syndromic poikiloderma and negative for RECQL4 sequencing analysis were investigated for C16orf57 mutations. Two C16orf57 heterozygous nonsense mutations (p.W81X and p.Y89X) were identified in a 5-year-old female child presenting with generalized poikiloderma, dental dysplasia,…

medicine.medical_specialtyHeterozygoteNeutropeniaNonsense mutationPoikilodermaNeutropeniaDiagnosis DifferentialGeneticsmedicineHumansAbnormalities MultipleGenetic TestingGenetics (clinical)Genetic testingRetrospective StudiesGeneticsmedicine.diagnostic_testRecQ HelicasesGenetic heterogeneitybusiness.industryRothmund-Thomson SyndromeGeneral Medicinemedicine.diseaseDermatologyPedigreePalmoplantar keratodermaCodon NonsenseChild PreschoolAbsolute neutrophil countErythrocyte CountFemalebusinessDyskeratosis congenitaEuropean journal of medical genetics
researchProduct

LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations?

2021

The Liver Imaging Reporting and Data System algorithm allows category downgrade in the presence of ancillary features (AFs) favoring benignity, even in observations categorized as LR-5. This study aims to assess the role of AFs favoring benignity in LR-5 observations and their impact on category downgrade. This study included high-risk patients with at least one LR-5 observation imaged with gadoxetate disodium MRI. Three readers with different experience levels independently evaluated the presence of AFs favoring malignancy (not hepatocellular carcinoma (HCC) in particular and HCC in particular) and AFs favoring benignity. Category downgrade was considered possible in the presence of ≥ 1 AF…

medicine.medical_specialtyHigh prevalenceCarcinoma Hepatocellularbusiness.industryBenignityLiver NeoplasmsContrast MediaGeneral MedicineMalignancymedicine.diseaseLiver Magnetic resonance imaging Cirrhosis Hepatocellular carcinoma Gadoxetate disodiumMagnetic Resonance ImagingSensitivity and SpecificitymedicineHumansRadiology Nuclear Medicine and imagingRadiologybusinessKappaLiver imagingRank correlationRetrospective StudiesEuropean radiology
researchProduct

Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multice…

2015

Lipoprotein apheresis (LA) can lower LDL-cholesterol and Lp(a) by 60%-70% and is the final escalating option in patients with hyperlipoproteinemias involving LDL or Lp(a) particles. Major therapeutic effect of LA is preventing cardiovascular events. In Germany since 2008 a reimbursement guideline has been implemented accepting to establish the indication for LA not only for familial or severe forms of hypercholesterolemia but also based on Lp(a)-hyperlipoproteinemia associated with a progressive course of cardiovascular disease, that persists despite effective treatment of other concomitant cardiovascular risk factors. The Pro(a)LiFe-study confirmed with a prospective multicenter design tha…

medicine.medical_specialtyHyperlipoproteinemiasTime FactorsDiseaseRisk AssessmentCoronary artery diseasePredictive Value of TestsRisk FactorsInternal medicineMulticenter trialGermanyInternal MedicinemedicineHumansProspective StudiesFamily historyRetrospective Studiesbiologybusiness.industryTherapeutic effectGeneral MedicineGuidelineLipoprotein(a)medicine.diseaseSurgeryTreatment OutcomeCardiovascular Diseasesbiology.proteinCardiologyBlood Component RemovalDisease ProgressionCardiology and Cardiovascular MedicineRisk assessmentbusinessBiomarkersLipoprotein(a)Atherosclerosis. Supplements
researchProduct

Retrospective Analysis of Whole-Body Magnetic Resonance Imaging of Bone Manifestations in Long-Term Treated Patients with Gaucher Disease Type 1

2018

We retrospectively assessed bone and visceral manifestations in patients with Gaucher disease type 1 (GD1) with whole-body magnetic resonance imaging (WB-MRI) to determine the effects of different timing in initiating long-term enzyme replacement therapy.In 17 patients with GD1, we performed 2 WB-MRI examinations at a median interval of 13 months. Patients had received enzyme replacement therapy with alglucerase/imiglucerase for a median of 13 years prior to the first examination. MRI results were retrospectively stratified based on treatment initiation into 2 groups: "early" (age ≤12 years, median 5 years) and "late" (during adulthood, median 32 years). We evaluated occurrence of irreversi…

medicine.medical_specialtyImiglucerase030232 urology & nephrologyDiseaseSeverity of Illness Index03 medical and health sciences0302 clinical medicineBone MarrowAlglucerase030225 pediatricsmedicineRetrospective analysisHumansEnzyme Replacement TherapyWhole Body ImagingRetrospective StudiesGaucher Diseasemedicine.diagnostic_testbusiness.industryOsteonecrosisMagnetic resonance imagingRetrospective cohort studyEnzyme replacement therapyMagnetic Resonance ImagingRecombinant ProteinsSurgeryTreatment OutcomePediatrics Perinatology and Child HealthGlucosylceramidaseWhole bodybusinessmedicine.drugKlinische Pädiatrie
researchProduct

Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis…

2022

Abstract Although each autoimmune disease is associated with specific tissue or organ damage, rheumatic diseases share a pro-inflammatory pattern that might increase cardiovascular risk. Retrospective and prospective studies on patients affected by systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) highlighted the concept of “accelerated atherosclerosis”. Therefore, the purpose of this systematic review and meta-analysis is the assessment of symptomatic or asymptomatic cardiovascular events among patients with rheumatic diseases as RA and SLE. The literature research obtained all manuscripts published in the English language between 2015 and 2019 for a total of 2355 manuscript…

medicine.medical_specialtyImmunologyDiseaseAsymptomaticArthritis RheumatoidRisk FactorsInternal medicinemedicineHumansLupus Erythematosus SystemicImmunology and AllergyProspective StudiesProspective cohort studyRetrospective StudiesAutoimmune diseasebusiness.industryIncidence (epidemiology)medicine.diseaseCardiovascular DiseasesHeart Disease Risk FactorsAge Cardiovascular events Metaanalysis Rheumatoid arthritis Risk Systemic lupus erythematosusMeta-analysisRheumatoid arthritisInclusion and exclusion criteriamedicine.symptombusinessAutoimmunity Reviews
researchProduct